Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.
暂无分享,去创建一个
A. Gabrielli | R. Rezzonico | J. Dayer | P. Meroni | R. Mallone | C. Chizzolini | N. Del Papa | A. Facchini | M. Borghi | E. Raschi | C. Testoni | Cinzia Testoni
[1] C. Chizzolini. T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples , 2004, Springer Seminars in Immunopathology.
[2] U. Haustein,et al. Lymphocytotoxic autoantibodies in progressive systemic sclerosis , 2004, Archives of Dermatological Research.
[3] N. Ronda,et al. Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. , 2002, Arthritis and rheumatism.
[4] Toshiyuki Yamamoto,et al. Monocyte Chemoattractant Protein-1 Enhances Gene Expression and Synthesis of Matrix Metalloproteinase-1 in Human Fibroblasts by an Autocrine IL-1α Loop1 , 2000, The Journal of Immunology.
[5] T. Yamamoto,et al. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. , 2000, Journal of immunology.
[6] F. Arnett,et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. , 1999, Arthritis and rheumatism.
[7] Y. Wu,et al. Intracellular IL-1 Receptor Antagonist Is Elevated in Human Dermal Fibroblasts That Overexpress Intracellular Precursor IL-1α , 1999, The Journal of Immunology.
[8] A. Rosen,et al. Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status , 1999, The Journal of experimental medicine.
[9] F. Arnett,et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. , 1999, Journal of immunology.
[10] Sato,et al. Augmented production of chemokines (monocyte chemotactic protein‐1 (MCP‐1), macrophage inflammatory protein‐1α (MIP‐1α) and MIP‐1β) in patients with systemic sclerosis: MCP‐1 and MIP‐1α may be involved in the development of pulmonary fibrosis , 1999 .
[11] C. Ponticelli,et al. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-infiammatory phenotype in vitro , 1999, Lupus.
[12] T. Wright,et al. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A , 1999 .
[13] M. Hasegawa,et al. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. , 1999, Clinical and experimental immunology.
[14] T. Wright,et al. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. , 1999, The Journal of clinical investigation.
[15] J. Korn,et al. Biology of the scleroderma fibroblast. , 1998, Current opinion in rheumatology.
[16] R. Rezzonico,et al. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. , 1998, Arthritis and rheumatism.
[17] Abraham,et al. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers , 1998, Clinical and experimental immunology.
[18] H. Heiken,et al. The IgG Fc receptor family , 1998, Annals of Hematology.
[19] T. Krieg,et al. Pathogenesis of fibrosis: type 1 collagen and the skin , 1998, Journal of Molecular Medicine.
[20] H. Ihn,et al. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. , 1998, The Journal of rheumatology.
[21] G. Tsay,et al. Autoantigen components recognizable by scleroderma sera are exported via ectocytosis of fibroblasts. , 1997, British journal of rheumatology.
[22] M. Khamashta,et al. Endothelial Cells as a Target for Antiphospholipid Antibodies: Role of Anti‐Beta 2 Glycoprotein I Antibodies , 1997, American journal of reproductive immunology.
[23] M. Greaves,et al. Antibodies to membranes of endothelial cells and fibroblasts in scleroderma , 1996, Clinical and experimental immunology.
[24] Y. Okano,et al. Antinuclear antibody in systemic sclerosis (scleroderma). , 1996, Rheumatic diseases clinics of North America.
[25] A. Mantovani,et al. Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. , 1996, Arthritis and rheumatism.
[26] C. Savage,et al. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. , 1996, The Journal of clinical investigation.
[27] P. Boros,et al. Circulating Fcγ receptor-specific autoantibodies in localized and systemic scleroderma , 1995 .
[28] P. Boros,et al. Circulating Fc gamma receptor-specific autoantibodies in localized and systemic scleroderma. , 1995, Journal of the American Academy of Dermatology.
[29] S. Jimenez,et al. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. , 1995, Pathobiology : journal of immunopathology, molecular and cellular biology.
[30] M. De Carlo,et al. Interstitial exclusion of IgG in rat tissues estimated by continuous infusion. , 1994, The American journal of physiology.
[31] K. Bost,et al. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. , 1992, The Journal of rheumatology.
[32] O. Hornstein,et al. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. , 1992, Journal of the American Academy of Dermatology.
[33] S. Jimenez,et al. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. , 1992, Arthritis and rheumatism.
[34] J. Korn,et al. Regulation of ICAM-1 expression and function in human dermal fibroblasts by IL-4. , 1992, Journal of immunology.
[35] D. Charron,et al. Induction of interleukin‐1β production in human dermal fibroblasts by interleukin‐1α and tumor necrosis factor‐α. Involvement of protein kinase‐dependent and adenylate cyclase‐dependent regulatory pathways , 1991 .
[36] J. Johnson,et al. Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. , 1991, The Journal of investigative dermatology.
[37] D. Charron,et al. Induction of interleukin-1 beta production in human dermal fibroblasts by interleukin-1 alpha and tumor necrosis factor-alpha. Involvement of protein kinase-dependent and adenylate cyclase-dependent regulatory pathways. , 1991, Journal of Cellular Biochemistry.
[38] B. Needleman. Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. , 1990, Arthritis and rheumatism.
[39] M. Sticherling,et al. IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. , 1990, Journal of immunology.
[40] M. Moroni,et al. In vitro modulation of human endothelial cell growth by Kaposi's sarcoma sera. , 1990, Journal of acquired immune deficiency syndromes.
[41] F. Alderuccio,et al. Autoantibody to gp50, a glycoprotein shared in common between fibroblasts and lymphocytes, in progressive systemic sclerosis. , 1989, Clinical and experimental immunology.
[42] J. Seibold,et al. Anti-IgE autoantibodies in systemic sclerosis (scleroderma). , 1989, Annals of the rheumatic diseases.
[43] E. Vuorio,et al. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. , 1988, The Journal of investigative dermatology.
[44] T. Krieg,et al. Localization of collagen mRNA in normal and scleroderma skin by in‐situ hybridization , 1988, European journal of clinical investigation.
[45] T. Medsger,et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.
[46] C. Dinarello,et al. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. , 1986, The Journal of clinical investigation.
[47] S. Lolait,et al. Autoantibodies to fibroblasts in scleroderma. , 1982, Journal of clinical & laboratory immunology.
[48] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[49] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.
[50] N. Rossing. Intra- and extravascular distribution of albumin and immunoglobulin in man. , 1978, Lymphology.
[51] J. R. Reeves,et al. Cellular infiltrates in scleroderma skin. , 1977, Arthritis and rheumatism.